



## **Press Release**

### **MiP Pharma group remains on track for growth Expansion of the existing production facilities at the Homburg site**

**Blieskastel, January 17<sup>th</sup>, 2023. MiP Pharma Group is investing in its production site in Homburg, Saarland, expanding the existing facilities. This investment boosts the company's growth and creates new jobs locally.**

MiP Pharma Group produces and distributes prescription generics, especially antibiotics, over-the-counter medicines and medical products. With over 280 employees, the company reliably and sustainably contributes to securing the supply of medicines in Germany. With the further expansion of the facility at the Homburg site, the company is strengthening its production capacities in future-oriented technologies such as sterile production as well as its activities as a pharmaceutical contract manufacturer. The interior construction is also being funded by the Saarland; the total investment volume amounts to a two-digit million euro sum.

Dr Friedrich Sernetz, CEO MiP Pharma Group, explains: "We are excited about these recent investments in Homburg. They reaffirm our commitment to Saarland as a production location. We continue to grow and create new jobs in the region. In this way, we are focusing even more specifically on the production of indispensable medicines in Germany, strengthening the security of supply for patients locally."

Alexander Zamora, partner at the owner capiton AG, affirms: "Since the acquisition of MiP Pharma almost two years ago, we have been supporting the Group in its consistent growth strategy and providing the capital required for this. In the financial year 2021/22, the turnover of the MiP Pharma group of companies grew by approx. 15% to record results of around € 50 m. With the current investments in Homburg, this growth path is continuing."

#### **About MiP Pharma Group**

MiP Pharma Group (MiP Pharma) produces and distributes prescription generics, especially antibiotics, over-the-counter medicines and medical products. Its main markets are Germany and Poland as well as some other Eastern European markets. Sales focus the hospital business and selected groups of specialists and, in particular, dentists. MiP Pharma operates two production sites in Saarland/Germany. With over 280 employees and around 400 regulatory approvals, MiP Pharma generated total sales of over € 50 m in the last fiscal year. Since November 2020, previously family-run MiP Pharma has been a portfolio company of the Berlin-based financial investor capiton AG.



**Media Contact**

Evelyn Back

+49 176 636 13 964

[evelyn@backroberts.com](mailto:evelyn@backroberts.com)